Pages that link to "Q26822421"
Jump to navigation
Jump to search
The following pages link to Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics (Q26822421):
Displaying 50 items.
- Emerging and future therapies for hemophilia (Q26781143) (← links)
- Anti-infective immunoadhesins from plants (Q26799080) (← links)
- A perspective on the structure and receptor binding properties of immunoglobulin G Fc (Q26827579) (← links)
- The Role of FcRn in Antigen Presentation (Q26852988) (← links)
- Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice (Q27321626) (← links)
- The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy (Q28257521) (← links)
- Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids (Q30279245) (← links)
- Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development (Q30395677) (← links)
- Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype (Q30491639) (← links)
- Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications (Q30834514) (← links)
- Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. (Q34045763) (← links)
- Regulation of immune responses by the neonatal fc receptor and its therapeutic implications (Q34818194) (← links)
- Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance (Q35168244) (← links)
- Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice (Q35212305) (← links)
- Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates (Q35531873) (← links)
- FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes (Q35612397) (← links)
- A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent. (Q35643633) (← links)
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. (Q35670904) (← links)
- Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1. (Q35743857) (← links)
- Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. (Q36212739) (← links)
- Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn (Q36214076) (← links)
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding (Q36510864) (← links)
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. (Q37489013) (← links)
- Changing paradigm of prophylaxis with longer acting factor concentrates (Q38206858) (← links)
- Chimeric fusion proteins used for therapy: indications, mechanisms, and safety (Q38400396) (← links)
- Longer-acting clotting factor concentrates for hemophilia (Q38543283) (← links)
- New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins (Q38574414) (← links)
- Monoclonal antibodies: technologies for early discovery and engineering (Q38633596) (← links)
- Eftrenonacog Alfa: A Review in Haemophilia B. (Q38711095) (← links)
- Quantification of IgG monoclonal antibody clearance in tissues (Q38726179) (← links)
- Antibody Engineering for Pursuing a Healthier Future (Q38731632) (← links)
- Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model (Q38760836) (← links)
- Half-life extended biotherapeutics (Q38770067) (← links)
- Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. (Q38799374) (← links)
- Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. (Q38828174) (← links)
- Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway (Q38846512) (← links)
- The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. (Q38867485) (← links)
- Efmoroctocog Alfa: A Review in Haemophilia A. (Q38917306) (← links)
- The ever-expanding myokinome: discovery challenges and therapeutic implications (Q38951385) (← links)
- Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein (Q38996905) (← links)
- Recent advances in (therapeutic protein) drug development. (Q39148639) (← links)
- Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates. (Q39204747) (← links)
- Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice (Q39830501) (← links)
- Ephrin-B2/Fc promotes proliferation and migration, and suppresses apoptosis in human umbilical vein endothelial cells (Q41092476) (← links)
- Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. (Q41168032) (← links)
- APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. (Q41355686) (← links)
- Artificial DnaJ Protein for protein production and conformational diseases (Q41446947) (← links)
- The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity (Q41469628) (← links)
- A Peptide-Fc Opsonin with Pan-Amyloid Reactivity (Q41471564) (← links)
- Chicken IgY Fc Linked to Bordetella avium ompA and Taishan Pinus massoniana Pollen Polysaccharide Adjuvant Enhances Macrophage Function and Specific Immune Responses (Q41631517) (← links)